Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
An excellent review/focus from R Storb. His fazit, " Therefore, faced with the choice of an HLA-identical sibling marrow  graft or even an alternative donor graft vs immunosuppression, many  patients should be counseled in favor of marrow transplantation as  first-line therapy."   Presenter:Prof. Spyridonidis Participants:Dr. Liga, Dr.Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A recent study published in Blood advances "Evaluation of induction  chemotherapies after hypomethylating agent failure in myelodysplastic  syndromes and acute myeloid leukemia" was presented. Induction led to response in 41% and 32%, survival of 10.8 and 6 months,  and transplant in 40% and 42% of responders in MDS...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
We discussed the emerging data of the importance of asparaginase in the  treatment of ALL. We discussed the potential toxicities and how we can  manage them. The time point of application plays after cheotherpay is of  major importance. Monitoring for pancreatitis and bleeding should be  done routinely. Presenter: Prof....
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
We discussed the current literature regarding the role of allo HCT in  the era of BV and PD1 blockade for HD. Patients with cHL who are ineligible for auto-HCT or relapse after  auto-HCT have historically had a poor prognosis with a median survival  of 2 years or...
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
A patient with JAkavi resistant LF who was referred to our unit was  presented and discussed. We also presented the current How I treat paper  form Blood. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
2018-W15 : Update on CLL treatment algorithm.
The Oncopedia 2018 update on CLL treatment algorithm has presetend and  discussed. Presenter: Prof. Spyridondis Partricpants: Dr Liga, Dr Spyridis, Dr Aggelinas  
Καταχωρήθηκε: Δευτέρα 20 Αύγ 2018
Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas   Main studies in newly diagnosed MM (NDMM) presented in 23. Congress, European Hematology Association (EHA), Stockholm, Sweden.   ALCYONE NDMM, >65y, auto non-eligible Daratumumab (D) plus Bortezomib-Melphalan-Prednison (VMP) vs VMP more CR, PFS nr vs 20,4 Mo, no problems with addtion of Daratumumab  GIMEMA  Phase-3, NDMM  Bortezomib, Thalidomid-Dexamethason (VTD) vs TD, pre...
Καταχωρήθηκε: Πέμπτη 09 Αύγ 2018
Presenter: Dr Liga Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Τρίτη 31 Ιούλ 2018
The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was presented. Presenter: Prof:Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Καταχωρήθηκε: Τετάρτη 25 Ιούλ 2018
Goal of the educational session is to understand the role of DPB1 mismatched in allo Tx. We discussed their level of expression and  their alloreactivity as is scored in the TCE algorithm. We also discussed a new proposed methodology which defines the DPB1 alloreactivity...
Καταχωρήθηκε: Πέμπτη 19 Ιούλ 2018
Scope: To update the current treatment management of CLL in the elderly. Presenter: Dr Spyridis Participants: Prof. Spyridonidis, Dr Liga, Dr Aggelinas.
Καταχωρήθηκε: Τετάρτη 18 Ιούλ 2018
Based on a case we discussed the current treatment guidelines for essential thrombocythemia. Dr Spyridis presented the current How I treat Blood paper. Presenter: Dr Spyridis Participants: Prof: Spyridonidis, Dr Liga, Dr Aggelinas
Καταχωρήθηκε: Τετάρτη 11 Ιούλ 2018
We discussed a recent review of the Treatment Options for Carbapenem- Resistant Gram-Negative Infections. We additionally reviewed our current policy in treating these infections and implemented a new policy. Presenter: Prof. Marangos Participants: Prof. Spyridonidis, Dr Spyridis, Dr Liga, Dr Aggelinas.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
We discussed novel insights regarding the pathophysiology of CRS after CART therapy published in Nature Medicine. Activation of macrophages plays a major role.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: The Hellenic experience of the use of BV in relapsed HD was presented. The need for transplant after achieving some disease control was discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: We discussed the legislation about SEC and other terms such as GRID. The legislation was presented, especially the specific issue regarding BMT units in Greece which will be presented in EU TE Compenidum. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adopt this strategy. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adapt this strategy. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: To present the analysis of our transplant strategy. Results of the analysis of about 100 transplants is shown. Dr Maria Liga presented us her database. Prof. Spyridonidis explained how the data were analysed. The decision to add Cellcept in the case of a...
Καταχωρήθηκε: Δευτέρα 09 Ιούλ 2018
Goal: The use of TKIs post transplant to prevent relapse. A recent paper describing how sorafenob in mflt3 mutant AML promotes the local GVL effect is presented.  Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas
Βρέθηκαν 269 αποτελέσματα. Σελίδα 8 από 14
Σελίδα << < [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας